**Instructions:** Complete staff initials next to procedures completed. Do not initial for other staff members. If other staff members are not available to initial checklist items themselves, initial and date a note on the checklist documenting who completed the procedure, e.g., “done by {name}” or “done by nurse.” If a procedure listed on the checklist is not performed, enter “ND” for “not done” or “NA” for “not applicable” beside the item and record the reason why (if not self-explanatory); initial and date this entry. If any procedures are not conducted on the date recorded above, ensure the date procedure conducted is included in the comments section.

| **Procedure** | | **Staff Initials** | **Comments:** |
| --- | --- | --- | --- |
|  | Confirm identity and PTID |  |  |
|  | Check for co-enrollment in other studies per site SOPs:   * NOT enrolled in another study ⇒ CONTINUE. * Enrolled in another study ⇒ STOP. Consult the PSRT regarding on-going product use and safety considerations. |  |  |
|  | Review elements of informed consent/assent as needed. Explain procedures to be performed at today’s visit. |  |  |
|  | Review/update locator information using site-specific form. |  |  |
|  | Provide available test results from previous visit. Treat and/or refer for care as required. |  |  |
|  | Log into the MTN-034 Medidata Rave database, and select the appropriate PTID. Open the applicable visit folder. Complete the **Follow-up Visit Y/N** **CRF.** |  |  |
|  | Administer the PUEV/Discontinuers A/CASI and document on the **ACASI Summary** and **ACASI Tracking CRFs** per the participant’s visit type and the product she has been using prior to this visit:   |  |  | | --- | --- | | * Scheduled PUEV * Ring * Tablet * No Product | * Early Study Discontinuation * Ring * Tablet * No Product *(Period 3 only)* | |  |  |
|  | Review/ updateany **Social Impact Log** and **Social Benefits Log CRF(s).**  Administer the **Social Benefits and Impact CRF** and complete new **Social Impact/ Social Benefits Log CRFs**, as applicable. |  |  |
|  | Collect follow-up medical/contraceptive/medications history and document any Adverse Events; review/update:   * **Adverse Event Log CRF** * **Concomitant Medications Log CRF** * **Family Planning Log CRF** |  |  |
|  | **For early termination ONLY:**   * Complete **Study Discontinuation CRF** and **Product Discontinuation Log CRF.** |  |  |
| * Complete **Study Exit Worksheet** and **Permission to Contact Log**. As indicated per protocol, arrange future contact for follow-up on ongoing AEs. |  |  |
|  | Collect mid-stream urine catch (15-60 mL) and perform tests:   * Urine hCG (pregnancy) * Dipstick urinalysis and/or culture per site SOP (if indicated) |  |  |
|  | Collect follow-up medical/contraceptive/medications history and document any Adverse Events; review/update:   * **Adverse Event Summary/ Log CRF** * **Concomitant Medications Log CRF** * **Family Planning Log CRF** |  |  |
|  | ***If indicated*,** provide contraceptive counseling and prescribe contraceptives as necessary. Document in chart notes and/or on **Contraceptive Counseling Worksheet.**  *Note: Counsel in case the participant is found to have stopped using or not liking current method; refer to Family Planning Log.* |  |  |
|  | Review pregnancy test results:   * NOT pregnant ==> CONTINUE. * Pregnant, pregnancy newly identified at today’s visit ==> HOLD.   + Complete If applicable, arrange to collect product not returned today within 24 hours.   + Initiate Pregnancy Management Worksheet *[site to delete if not using]* * Pregnant, pregnancy first identified at a previous visit ==> HOLD.   Complete **Pregnancy Test Result CRF.** |  |  |
|  | Administer and document HIV pre-testing using the **HIV Pre/Post Test and Risk Reduction Counseling Worksheet**. |  |  |
|  | Collect the following amounts of blood and send to lab for testing:   * HIV-1   + [X] mL [color] top [additive/no additive] tube * Dried blood spot (DBS) for PK   + [x]mL [color] top (no additive) tube * Plasma archive   + 10 mL [color] top (no additive) tube * HSV-2 antibody   + [X] mL [color] top [additive/no additive] tube * Syphilis serology   + [X] mL [color] top [additive/no additive] tube * Complete blood count (CBC) with platelets   + [X] mL [color] top [additive/no additive] tube * Blood creatinine (and calculated creatinine clearance)   + [X] mL [color] top [additive/no additive] tube     *Note: Label all required tubes with a SCHARP-provided PTID label at the time of collection. For MTN LC bound specimens, store frozen at site while awaiting shipping request.* |  |  |
|  | Perform and document rapid HIV tests per site SOPs. |  |  |
|  | Complete HIV test results and post-testing actions:   * Provide testing results and referrals if needed/requested per site SOPs. * If both tests negative = UNINFECTED ⇒CONTINUE. * If both tests positive = INFECTED ⇒ STOP ***or,*** * If one test positive and one test negative = DISCORDANT ⇒ STOP. * Collect blood for CBC with platelets, PK and serum creatinine (for calculated creatinine clearance – take height). measurement as well)\* * Collect vaginal samples for biomarkers\* * Follow Protocol HIV Testing Algorithm for follow-up actions based on confirmation test results. * Provide and document HIV post-test and HIV/STI risk reduction counseling using the **HIV Pre/Post Test and Risk Reduction Counseling Worksheet**\*\* * Offer condoms. * Document test results onto **HIV Test Results** **CRF** and **HIV Confirmatory Results**, if indicated.   *\* If samples have not already been collected.*  *\*\*Modify HIV risk reduction counseling if necessary.* |  |  |
|  | Perform and document FULL physical exam. Complete **Vital Signs CRF** and **Physical Exam CRF**. |  |  |
|  | Complete **Study Product Request Slip** by marking “Product Use Complete” and send to pharmacy. |  |  |
|  | **For participants using the ring**:   * N/A (if not using ring)   Have participant (or clinician/designee) remove used ring. Collect used ring, send to lab for storage, and document on **Site-Specific Clinic Study Product Accountability Log, Specimen Storage CRF,** **Ring Insertion and Removal CRF,** and **Product Discontinuation Log CRF** |  |  |
|  | **For participants using the study tablet:**   * N/A (if not using tablet)   Collect any study tablet bottle and send back to pharmacy. Document on **Site-Specific Clinic Study Product Accountability Log**, **PrEP Provisions and Returns CRF,** and **Product Discontinuation Log CRF** |  |  |
|  | Perform and document a pelvic exam per the Pelvic Exam Checklist, including sample collection. Document on **Pelvic Exam Diagrams** and **Pelvic Exam CRF.** |  |  |
|  | Evaluate findings identified during pelvic and physical examinations and medical and menstrual history review. Document in chart notes and update **Concomitant Medications Log, AE Summary/Log** **CRFs**, if applicable. Document ongoing conditions on the **AE Log CRF**. |  |  |
|  | If not vaccinated against HPV and/or HBV, offer. If accepted, provide or refer for HBV and/or HPV vaccine series. Document on in **chart notes** and confirmed provision of each dose on the **Concomitant Medications Log CRF.**  *NOTE: For enrolled participants who decline vaccination at enrollment, the vaccine series may be initiated at any time during follow-up.* |  |  |
|  | Provide and explain all available findings and results to participant. Refer for other findings as indicated.  ***If indicated****,* treat for STI/RTI/UTI per site SOP. |  |  |
|  | Complete the **Follow-up Visit Summary CRF.** |  |  |
|  | Perform QC1: while participant is still present, review the following for completion:   * **Follow-Up Y/N and Follow-up Visit Summary** to ensure all items are complete. * **Social Impact/Benefits related CRFs** and **ACASI CRFs** are complete. * **AE Logs CRFs,** **Family Planning Log, and Concomitant Medications Log** to ensure all conditions, medications, AEs are captured consistently and updated. * **Site-Specific Clinic Study Product Accountability Log** and **Ring Collection and Insertion** or **PrEP Provisions and Returns CRF** are constantly completed. * **Chart notes** to ensure complete and accurate * **Physical, Pelvic, Vital Signs, HIV Test, Pregnancy Test Results, STI Test Results CRFs** completed for Physical and Pelvic exam and testing documentation. |  |  |
|  | **PUEV Only:** Schedule final contact/visit (V24).\* Provide contact information and instructions to report symptoms and/or request information, counseling, or condoms before next visit.  *\*May be conducted by phone.* |  |  |
|  | Refer to **Qualitative Participation Log (QPL)** to see if participant is to participate in a late FDG\*   * If **yes**, confirm availability or date of FDG if already scheduled (must occur prior to Visit 24) * Late FDG already completed (permitted as early as Visit 20) * Not participating in an FDG   *\*subset of participants only* |  |  |
|  | Provide reimbursement |  |  |
|  | Perform QC2 review and ensure that data is entered in Medidata for the following CRFs/forms:  Required CRFs   * ACASI Summary/ ACASI Tracking * Follow-up Y/N * Follow-up Visit Summary * HIV Test Results * Local Laboratory Results * Physical Exam * Pelvic Exam * Social Benefits and Impacts * Specimen Storage * Vital Signs * STI Test Results * Pregnancy Test Result * Product Discontinuation Log * Ring Insertion and Removal, or PrEP Provisions and Returns Log *(per participant’s study arm)*   *As needed*   * Social Impacts Log * Social Benefits Log * Adverse Events Log * Concomitant Medications Log * Study Discontinuation * Family Planning Log   Paper Forms:   * Pelvic Exam Diagrams * LDMS Specimen Tracking Sheet * Site-Specific Clinic Study Product Accountability Log * HIV Pre-/Post-Test and Risk Counseling Worksheet   *If indicated/applicable*   * Contraceptive Counseling Worksheet * Qualitative Participation Log (QPL) * Study Product Request Slip * Pregnancy Management Worksheet * Study Exit Worksheet * Permission to Contact Log |  |  |